UEG's content platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Re-live UEG Week 2026 on Gutflix Gut Guide online What's new on Gutflix

Trending on Gutflix

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Audio / Video Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

ONLINE EDUCATION SIGNIFICANTLY IMPROVED GASTROENTEROLOGISTS’ UNDERSTANDING OF THE USE OF ULTRASOUND IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASE

Elaine Bell 1, Marinella Calle 1

Affiliations

1 Medscape Global, London, United Kingdom

Summary

AI Generated

An online educational activity with video lecture and embedded ultrasound images significantly improved gastroenterologists' knowledge and confidence in using intestinal ultrasound to manage inflammatory bowel disease patients.

Among 195 gastroenterologists, average correct responses on knowledge questions increased from 46% at baseline to 64% post-activity (P <.001), with moderate educational impact (Cohen's d=0.60).
Knowledge improved significantly on ECCO-ESGAR guideline recommendations (54% to 65%, P <.01), stricture detection via bidirectional stool content (55% to 70%, P <.001), and bowel wall thickness >4mm as the most sensitive parameter for active Crohn disease (28% to 58%, P <.001).
After the activity, 44% of gastroenterologists reported improved confidence in interpreting intestinal ultrasound images to support IBD management, with a 79% confidence shift.
The 30-minute activity included a video lecture by Dr. Gerhard Rogler with synchronized slides and embedded ultrasound videos showing real-life clinical images and their interpretation.
Gastroenterologists managing IBD patients who seek to expand their use of intestinal ultrasound in clinical decision-making would benefit from this type of education.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Intestinal ultrasound (IUS) offers a number of advantages over endoscopy in monitoring and managing patients with inflammatory bowel disease (IBD) but despite the wide availability of IUS, it remains underused to support decision-making in clinical practice.

Aims & Methods

We aimed to determine whether online accredited education could improve gastroenterologists’ knowledge of best practice in the use of IUS to monitor and manage patients with IBD, and could enhance their confidence in using IUS in clinical practice.
Gastroenterologists participated in a 30-minute video lecture with synchronized slides and embedded IUS videos entitled ‘Gastrointestinal Ultrasound in the Management of IBD’. Responses to 3 multiple-choice, knowledge questions and 1 self-efficacy, 5-point Likert scale confidence question were analyzed. Educational effect was assessed using a repeated-pair design, pre-/post-assessment. A paired samples t-test was conducted for significance testing on overall average number of correct responses and for confidence rating. A series of McNemar’s tests were conducted at the question level (5% significance level, P <.05). Cohen’s d with correction for paired samples estimated the effect size of the education on number of correct responses (<.20 modest, .20-.49 small, .59-.79 moderate, ≥.80 large). The activity launched on 1 February 2021 with data collection through 12 April 2021.

Results

Gastroenterologists (n=195) significantly improved their knowledge of the ECCO-ESGAR guideline recommendations on the use of IUS in IBD (54% correct responses at baseline rising to 65% post-activity; P <.01), that stool content going in both directions in IUS is indicative of stricture (55% correct responses at baseline rising to 70% post-activity; P <.001), and that bowel wall thickness >4mm in a patient with Crohn Disease is the most sensitive IUS parameter indicating active disease i.e. treatment failure (28% correct responses at baseline rising to 58% post-activity; P <.001)
The proportion of gastroenterologists answering all 3 questions correctly rose from 9% at baseline to 35% post-activity
The average percentage of correct responses increased from 46% at baseline to 64% post-activity (P <.001), and there was a moderate educational impact (Cohen’s d=0.60)
After completing the activity, 44% of gastroenterologists reported improved confidence in in interpreting IUS images to support the management of patients with IBD, resulting in a notable confidence shift of 79%
92% of gastroenterologist responders felt the education would improve their performance, resulting in improved patient outcomes

Conclusion

This online activity significantly improved gastroenterologists' knowledge and confidence in the use of IUS in IBD management. Gastroenterologists would likely benefit from additional education to embed their knowledge on the use of IUS and improve their confidence in interpreting IUS images to support decision-making in clinical practice.

Conference

UEG Week Copenhagen 2023

Submission format

Abstract

Session

PP 10 Health economics / Digitalisation in GI / Education In GI / Gender and diversity (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

More Like This:

How to maintain adherence and consistent follow-up in coeliac disease

Carolina Ciacci

Q&A: Comparative discussion: Choosing the right tool for the right patient

FIRST MULTIDEVICE ARTIFICIAL INTELLIGENCE MODEL FOR INTRAOPERATIVE PREDICTION OF COLORECTAL ANASTOMOTIC LEAKAGE

Guilherme Macedo

DEEP LEARNING AND CAPSULE ENDOSCOPY: AUTOMATIC PANENDOSCOPIC DETECTION OF VASCULAR LESIONS

João Ferreira

The transition from acute to chronic pancreatitis: Can we stop it?

Bálint Erőss

TOWARD A SAFER, NON-SYSTEMIC JAK INHIBITOR FOR IBD: A PHASE 2A STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PRELIMINAR CLINICAL EFFICACY OF ORAL TREATMENT WITH OST-122 IN PATIENTS WITH ULCERATIVE COLITIS

María Dolores Martín-Arranz

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

How to maintain adherence and consistent follow-up in coeliac disease

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

How to maintain adherence and consistent follow-up in coeliac disease

Carolina Ciacci 1

Affiliations

1 University of Salerno, Salerno, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Barcelona 2026

Topics

Small Intestine & Nutrition Paediatrics Oesophagus Immunology IBD

Session

Transitioning into adulthood in gastroenterology

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

How to maintain adherence and consistent follow-up in coeliac disease

Carolina Ciacci

Q&A: Comparative discussion: Choosing the right tool for the right patient

FIRST MULTIDEVICE ARTIFICIAL INTELLIGENCE MODEL FOR INTRAOPERATIVE PREDICTION OF COLORECTAL ANASTOMOTIC LEAKAGE

Guilherme Macedo

DEEP LEARNING AND CAPSULE ENDOSCOPY: AUTOMATIC PANENDOSCOPIC DETECTION OF VASCULAR LESIONS

João Ferreira

The transition from acute to chronic pancreatitis: Can we stop it?

Bálint Erőss

TOWARD A SAFER, NON-SYSTEMIC JAK INHIBITOR FOR IBD: A PHASE 2A STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PRELIMINAR CLINICAL EFFICACY OF ORAL TREATMENT WITH OST-122 IN PATIENTS WITH ULCERATIVE COLITIS

María Dolores Martín-Arranz

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Q&A: Comparative discussion: Choosing the right tool for the right patient

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Q&A: Comparative discussion: Choosing the right tool for the right patient

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

Postgraduate Teaching Programme Barcelona 2026

Topics

IBD

Session

Monitoring of disease activity in IBD

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

How to maintain adherence and consistent follow-up in coeliac disease

Carolina Ciacci

Q&A: Comparative discussion: Choosing the right tool for the right patient

FIRST MULTIDEVICE ARTIFICIAL INTELLIGENCE MODEL FOR INTRAOPERATIVE PREDICTION OF COLORECTAL ANASTOMOTIC LEAKAGE

Guilherme Macedo

DEEP LEARNING AND CAPSULE ENDOSCOPY: AUTOMATIC PANENDOSCOPIC DETECTION OF VASCULAR LESIONS

João Ferreira

The transition from acute to chronic pancreatitis: Can we stop it?

Bálint Erőss

TOWARD A SAFER, NON-SYSTEMIC JAK INHIBITOR FOR IBD: A PHASE 2A STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PRELIMINAR CLINICAL EFFICACY OF ORAL TREATMENT WITH OST-122 IN PATIENTS WITH ULCERATIVE COLITIS

María Dolores Martín-Arranz

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

FIRST MULTIDEVICE ARTIFICIAL INTELLIGENCE MODEL FOR INTRAOPERATIVE PREDICTION OF COLORECTAL ANASTOMOTIC LEAKAGE

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

FIRST MULTIDEVICE ARTIFICIAL INTELLIGENCE MODEL FOR INTRAOPERATIVE PREDICTION OF COLORECTAL ANASTOMOTIC LEAKAGE

Miguel Mascarenhas-Saraiva 1, Francisco Mendes 1, André Martins dos Santos 1, Filipa Fonseca 1, Larissa Mercadante de Assis 2, Felix Bonilla 2, Gonçalo Soares 3, Daniela Cavadas 4, Miguel Martins 1, Maria Almeida 1, Joana Mota 1, Ali Murtada 5, Marley Feitosa 6, Matheus Carvalho 2, Filipe Marques 7, João Ferreira 7, Ahsan Javed 5, Shakil Ahmed 5, Maisa Vasconcellos 6, Carlos Frederico Sparapan Marques 2, Manuel Limbert 4, Guilherme Macedo 1

Affiliations

1 Centro Hospitalar São João, Porto, Portugal

2 Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil

3 Centro Hospitalar Universitário de Santo António, Porto, Portugal

4 Instituto Português de Oncologia de Lisboa, Lisboa, Portugal

5 Royal Liverpool University Hospital NHS Foundation Trust, Liverpool, United Kingdom

6 Hospital das Clínicas da Faculdade de Medicina da USP de Ribeirão Preto, Ribeirão Preto, Brazil

7 Faculdade de Engenharia da Universidade do Porto, Porto, Portugal

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Anastomotic leakage (AL) is the postoperative complication with the greatest impact on both patients and healthcare systems after colorectal surgery, carrying substantial morbidity and mortality. Current assessment remains suboptimal and relies exclusively on clinical, radiological, and analytical parameters, often leading to delayed diagnosis and worse outcomes. Artificial intelligence (AI) in digestive healthcare has enabled the development of several detection (CADe) and characterization (CADx) models, although CADex models remain scarce. This study aimed to develop a multidevice deep learning model for intraoperative risk stratification, enabling real time prediction of AL.

Aims & Methods

An AI model based on a convolutional neural network was developed to predict AL using laparoscopic video frames, with a bounding box highlighting the region contributing most to leak prediction. AL diagnosis was established according to clinical, analytical, and imaging criteria. Normal anastomosis required stoma closure and at least 6 months of clinical follow up. To prevent overfitting and selection bias, dataset splitting was performed at the case level, ensuring that frames from the same surgery were not represented in both training and testing sets. The dataset was divided into training and testing sets using an 80 percent and 20 percent split. The detection component (CADe) was evaluated with mAP50, whereas the characterization component (CADx) was evaluated with accuracy and AUC ROC.

Results

This multicenter study included 71 colorectal surgeries and 17,801 frames collected across 4 reference centers in Europe and the Americas, using seven different laparoscopy systems, including conventional and robotic platforms. Thirteen patients developed CAL during postoperative follow up, whereas the remaining patients had an uneventful recovery without CAL. The AI model detected anastomoses with an mAP50 of 0.973. Frames associated with AL were identified with 99.0 percent accuracy and an AUC ROC of 0.997.

Conclusion

This is the first multidevice, interoperable AI model for intraoperative risk stratification enabling automatic prediction of AL development through a CADe mechanism for anastomosis identification, in a cohort including patients from both Europe and the Americas. The development of prognosis driven AI models is essential to support intraoperative decision making, allowing risk reduction through targeted preventive or active measures. Ultimately, these tools may reduce the incidence of this postoperative complication, with meaningful benefit for both patients and healthcare systems.

Event

UEG Week Barcelona 2026

Topics

Endoscopy Surgery Mechanisms & Personalised Medicine Colorectal

Submission format

Abstract

Session

Lower GI disorders: A multidisciplinary approach

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

How to maintain adherence and consistent follow-up in coeliac disease

Carolina Ciacci

Q&A: Comparative discussion: Choosing the right tool for the right patient

FIRST MULTIDEVICE ARTIFICIAL INTELLIGENCE MODEL FOR INTRAOPERATIVE PREDICTION OF COLORECTAL ANASTOMOTIC LEAKAGE

Guilherme Macedo

DEEP LEARNING AND CAPSULE ENDOSCOPY: AUTOMATIC PANENDOSCOPIC DETECTION OF VASCULAR LESIONS

João Ferreira

The transition from acute to chronic pancreatitis: Can we stop it?

Bálint Erőss

TOWARD A SAFER, NON-SYSTEMIC JAK INHIBITOR FOR IBD: A PHASE 2A STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PRELIMINAR CLINICAL EFFICACY OF ORAL TREATMENT WITH OST-122 IN PATIENTS WITH ULCERATIVE COLITIS

María Dolores Martín-Arranz

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

DEEP LEARNING AND CAPSULE ENDOSCOPY: AUTOMATIC PANENDOSCOPIC DETECTION OF VASCULAR LESIONS

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

DEEP LEARNING AND CAPSULE ENDOSCOPY: AUTOMATIC PANENDOSCOPIC DETECTION OF VASCULAR LESIONS

Miguel Martins 1, Miguel Mascarenhas-Saraiva 1, João Afonso 1, Tiago Ribeiro 1, Pedro Cardoso 1, Francisco Mendes 1, Maria João Almeida 1, Joana Mota 1, Ana Patrícia Andrade 1, Hélder Cardoso 1, João Ferreira 2, Guilherme Macedo 1

Affiliations

1 São João University Hospital, Porto, Portugal

2 Faculty of Engineering of University Porto, Porto, Portugal

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Capsule endoscopy (CE) is frequently employed as the first exam when mid-gastrointestinal bleeding is suspected, following normal upper and lower endoscopies. While its primary focus is on evaluating the small bowel, detection of vascular lesions both upstream and downstream could also hold clinical importance.

Aims & Methods

The aim of this study is to develop and test a Convolutional Neural Network (CNN)-based model for panendoscopic automatic detection of vascular lesions during CE. A retrospective study involving 2 centers was conducted, involving 1188 CE exams. A total of 152,312 frames were utilized, obtained from seven distinct types of CE devices, with 14,942 frames being classified as vascular lesions (angiectasias or varices) after triple validation. The data was divided in training/validation (90%) and test (10%) sets, using an exam-split design. A 5-fold cross-validation was conducted during training/validation set. The all process was iterated five times. The primary outcome measures were sensitivity, specificity, accuracy, area under the conventional receiver operating characteristic curve (AUC-ROC) and the precision-recall curve (AUC-PR), from the training/validation set.

Results

The model demonstrated a mean sensitivity and specificity of 87.5% (IC95% 81.5 – 93.6%) and 99.5% (IC95% 99.3 – 99.7%), respectively. Mean accuracy was 98.4% (IC95% 97.7 – 99.1%). Mean AUC-ROC value was 0.987 (IC95% 0.980 – 0.995), while AUC-PR value was 0.998 (IC95% 0.997 – 1.000).

Conclusion

This represents the first proof-of concept AI deep learning model developed for panendoscopic automatic detection of vascular lesions during CE. The CCN’s high diagnostic performance in multibrand devices addresses a critical issue of technological interoperability, allowing it to be replicated in multiple technological settings.

Event

UEG Week Vienna 2024

Topics

Endoscopy IBD

Submission format

Abstract

Session

AI in diagnostic and therapeutic endoscopy

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

More Like This:

How to maintain adherence and consistent follow-up in coeliac disease

Carolina Ciacci

Q&A: Comparative discussion: Choosing the right tool for the right patient

FIRST MULTIDEVICE ARTIFICIAL INTELLIGENCE MODEL FOR INTRAOPERATIVE PREDICTION OF COLORECTAL ANASTOMOTIC LEAKAGE

Guilherme Macedo

DEEP LEARNING AND CAPSULE ENDOSCOPY: AUTOMATIC PANENDOSCOPIC DETECTION OF VASCULAR LESIONS

João Ferreira

The transition from acute to chronic pancreatitis: Can we stop it?

Bálint Erőss

TOWARD A SAFER, NON-SYSTEMIC JAK INHIBITOR FOR IBD: A PHASE 2A STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PRELIMINAR CLINICAL EFFICACY OF ORAL TREATMENT WITH OST-122 IN PATIENTS WITH ULCERATIVE COLITIS

María Dolores Martín-Arranz

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

The transition from acute to chronic pancreatitis: Can we stop it?

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

The transition from acute to chronic pancreatitis: Can we stop it?

Bálint Erőss 1

Affiliations

1 Semmelweis University, Budapest, Hungary

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Barcelona 2026

Topics

Endoscopy Pancreas

Session

Life after acute pancreatitis: Risks, surveillance and management

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

How to maintain adherence and consistent follow-up in coeliac disease

Carolina Ciacci

Q&A: Comparative discussion: Choosing the right tool for the right patient

FIRST MULTIDEVICE ARTIFICIAL INTELLIGENCE MODEL FOR INTRAOPERATIVE PREDICTION OF COLORECTAL ANASTOMOTIC LEAKAGE

Guilherme Macedo

DEEP LEARNING AND CAPSULE ENDOSCOPY: AUTOMATIC PANENDOSCOPIC DETECTION OF VASCULAR LESIONS

João Ferreira

The transition from acute to chronic pancreatitis: Can we stop it?

Bálint Erőss

TOWARD A SAFER, NON-SYSTEMIC JAK INHIBITOR FOR IBD: A PHASE 2A STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PRELIMINAR CLINICAL EFFICACY OF ORAL TREATMENT WITH OST-122 IN PATIENTS WITH ULCERATIVE COLITIS

María Dolores Martín-Arranz

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

TOWARD A SAFER, NON-SYSTEMIC JAK INHIBITOR FOR IBD: A PHASE 2A STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PRELIMINAR CLINICAL EFFICACY OF ORAL TREATMENT WITH OST-122 IN PATIENTS WITH ULCERATIVE COLITIS

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

TOWARD A SAFER, NON-SYSTEMIC JAK INHIBITOR FOR IBD: A PHASE 2A STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PRELIMINAR CLINICAL EFFICACY OF ORAL TREATMENT WITH OST-122 IN PATIENTS WITH ULCERATIVE COLITIS

Manuel Barreiro-De Acosta 1, Svitlana Skybalo 2, Cristina Rodríguez Gutiérrez 3, Santiago García-López 4, María Dolores Martín-Arranz 5, Leyanira Torrealba 6, Eva Iglesias-Flores 7, Federico Argüelles-Arias 8, Yolanda Ber Nieto 9, Viktoriia Shevchuk 10, Cristina Castro Fernández 11, Julio César Castro-Palomino 11, Ascensión Heredia 11, Guido Kurz 11

Affiliations

1 Hospital Clínico Universitario de Santiago De Compostela, Santiago de Compostela, Spain

2 Medical Center “Ok!Clinic” of International Institute of Clinical Research LLC, Kyiv, Ukraine

3 Complejo Hospitalario Universitario de Navarra, Pamplona, Spain

4 Hospital Universitario Miguel Servet, Zaragoza, Spain

5 Hospital Universitario La Paz, Madrid, Spain

6 Hospital Universitario Dr. Josep Trueta, Girona, Spain

7 Hospital Universitario Reina Sofía, Córdoba, Spain

8 Universidad de Sevilla, Hospital Universitario Virgen Macarena, Sevilla, Spain

9 Hospital Universitario San Jorge, Huesca, Spain

10 Medical and Diagnostic Center PE PMC "Acinus", Kropyvnytskyi, Ukraine

11 Oncostellae S.L., Santiago de Compostela, Spain

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

JAK inhibitors have become an efficacious oral treatment option to antibody-based therapies for ulcerative colitis (UC). However, they have received a black box warning by the FDA for causing serious systemic adverse events.
To increase safety, OST-122 is being developed as an orally administered, GI-targeted and non-systemic JAK3/TYK2 inhibitor for the local treatment of UC. In preclinical models and in healthy volunteers, OST-122 has demonstrated excellent safety and tolerability with minimal systemic exposure reducing the risk of causing serious systemic toxicities associated with current JAK inhibitors.
Here, we report the results of a phase 2a study in patients with UC on the safety, tolerability, pharmacokinetics and preliminary efficacy of OST-122.

Aims & Methods

In this randomized, double-blind trial, 37 adult patients with active UC were treated with oral OST-122 400 mg (n=28) or placebo (n=9) for 28 days. Eligibility criteria required a total Mayo Score TMS 5-10, endoscopic Mayo Score EMS ≥2, inadequate/loss of response to conventional therapy (5-ASA, steroids, immunomodulators) or biologics (anti-TNFα, anti-integrin, anti-interleukin 12/23). Stable cotreatment with oral 5’ASAs and corticosteroids was permitted.
To evaluate the safety and tolerability of OST-122, the number and severity of AEs, including changes in vital signs, safety laboratory values and ECGs, were analyzed. Plasma, tissue and stool samples were collected at various time points to examine the gut-restricted pharmacokinetic profile of the compound in UC patients. Preliminary efficacy was assessed through Mayo Clinical Scores including rectal bleeding (RB) and stool frequency (SF) along with clinical response and remission.

Results

During the 6-week observation period, no serious AEs nor treatment-related AEs leading to discontinuation were reported. Most AEs were tabulated as mild, followed by moderate, and the number of subjects reporting AEs were distributed equally in the placebo and OST-122 group (78% vs. 71%). There were no clinically relevant changes in vital signs, laboratory values or ECG parameters which raise any safety concerns.
Pharmacokinetic analysis indicated minimal plasma concentrations (C_max 0.92 ng/mL) and therapeutically relevant levels in colon tissue (15.5 ug/g tissue) confirming a gut-restricted PK profile of OST-122.
Preliminary efficacy data after 28 days of treatment are summarized in the table below:

Outcome	400 mg OST-122 (n=28)	Placebo (n=9)	∆
Rectal Bleeding Improvement of RB score by ≥1	63% (17/27)	33% (3/9)	33%
Stool Frequency Improvement of SF score by ≥1	52% (14/27)	33% (3/9)	19%
PRO-2 score (RB + SF) Improvement of PRO-2 by ≥2	48% (13/27)	11% (1/9)	37%
Clinical Response Decrease of TMS by ≥3 or ≥30 %, plus improvement in RB by ≥1 and an absolute RB of 0 or 1	44% (12/27)	11% (1/9)	33%
Clinical Remission TMS ≤2 and no individual subscore >1, plus RB of 0	22% (6/27)	0% (0/9)	22%

63% of patients taking OST-122 showed an improvement in rectal bleeding and 52% in stool frequency (vs 33% in the placebo group), and 48% had an improvement of ≥2 in PRO-2 (RB+SF, vs 11% Pbo). Clinical response was achieved by 44% (vs 11% Pbo) and 22% reached clinical remission (vs 0% Pbo). In addition, 16% of patients in the OST-122 group achieved both histological response and remission (vs 0% Pbo). A subgroup analysis showed that OST-122 was able to induce clinical response both in bionaïve and bioexperienced patients. Confirmatory studies will be designed to determine dose and statistical significance.

Conclusion

GI-restricted OST-122 was well tolerated during the 4-week treatment. Its excellent safety profile, minimal systemic exposure and promising trends of clinical activity may provide a safer therapeutic option for a broad range of ulcerative colitis patients.

Disclosure

M. Barreiro de Acosta has served as a speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, Gillead, Celgene, Pfizer, Sandoz, Biogen, Fresenius, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, Gebro Pharma, Adacyte, Vifor Pharma and Oncostellae.
C. Rodríguez has received consultancy and/or speaking honoraria fees from AbbVie, Ferring, Galapagos, Janssen, Pfizer, Lilly and Takeda.
M.D. Martin-Arranz has received fees as a speaker, consultant and advisory member for or has received funding from MSD, AbbVie, Hospira, Pfizer, Takeda, Janssen, Shire Pharmaceuticals, Tillots Pharma, and Faes Pharma.
L. Torrealba has served as a speaker for Janssen.
E. Iglesias Flores has served as a speaker, consultant and advisory member for or has received research funding from AbbVie, Janssen, Takeda, Gillead, Celgene, Pfizer, Lilly, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, and Adacyte.
F. Argüelles-Arias has served as a speaker, consultant and advisory member or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, Gillead, Celgene, Pfizer, Sandoz, Biogen, Fresenius, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, Gebro Pharma, Adacyte and Vifor Pharma.
Y. Ber-Nieto has served as a speaker from Abbvie and has received education funding from Abbvie and Pfizer.

Event

UEG Week Vienna 2024

Topics

IBD Mechanisms & Personalised Medicine

Submission format

Abstract

Session

IBD: New horizons in medical treatment - Part 2

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

More Like This:

How to maintain adherence and consistent follow-up in coeliac disease

Carolina Ciacci

Q&A: Comparative discussion: Choosing the right tool for the right patient

FIRST MULTIDEVICE ARTIFICIAL INTELLIGENCE MODEL FOR INTRAOPERATIVE PREDICTION OF COLORECTAL ANASTOMOTIC LEAKAGE

Guilherme Macedo

DEEP LEARNING AND CAPSULE ENDOSCOPY: AUTOMATIC PANENDOSCOPIC DETECTION OF VASCULAR LESIONS

João Ferreira

The transition from acute to chronic pancreatitis: Can we stop it?

Bálint Erőss

TOWARD A SAFER, NON-SYSTEMIC JAK INHIBITOR FOR IBD: A PHASE 2A STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PRELIMINAR CLINICAL EFFICACY OF ORAL TREATMENT WITH OST-122 IN PATIENTS WITH ULCERATIVE COLITIS

María Dolores Martín-Arranz